钠-葡萄糖协同转运蛋白2抑制剂对射血分数保留型心力衰竭治疗的研究进展

Research Progress in Sodium-Glucose Co-Transporter 2 Inhibitors for Heart Failure with Preserved Ejection Fraction

射血分数保留型心力衰竭(heart failure with preserved ejection fraction,HFpEF)是持续的研究热点,其产生的损伤严重影响患者的生活质量,积极探索改善HFpEF预后的治疗方法十分重要。钠-葡萄糖协同转运蛋白2(sodium glucose co-transporter 2,SGLT-2)抑制剂不仅具有降血糖功能,对HFpEF患者的治疗也可能具有指导价值。文章回顾HFpEF现状、SGLT-2抑制剂作用机制以及SGLT-2抑制剂对HFpEF治疗研究的进展,证明SGLT-2抑制剂可能是改善HFpEF患者临床早期健康状况和生活质量的有力证据,并指出其具有一定的治疗意义和应用价值。未来也需要更丰富且深入的研究进一步肯定SGLT-2抑制剂对HFpEF患者的治疗效果。

Heart failure with preserved ejection fraction(HFpEF)is an ongoing research hotspot,and seriously affects the quality of life of patients.It is very important to actively explore the treatment methods to improve the prognosis of HFpEF.Sodium-glucose co-transporter 2(SGLT-2)inhibitors are independent of their hypoglycemic function and may have guiding value in the treatment of patients with HFpEF.This paper reviews the current status of HFpEF,the mechanism of action of SGLT-2 inhibitors,and the progress of SGLT-2 inhibitors in the treatment of HFpEF.It is strongly suggested that SGLT-2 inhibitors may improve early health status and quality of life of HFpEF patients and have certain therapeutic significance and application value.In the future,more abundant and in-depth studies are needed to further confirm the therapeutic effect of SGLT-2 inhibitors on patients with HFpEF.